NewsRelease

Malariaresearch article cites use of HemogloBind^TMin reticulocyte study

MONMOUTHJUNCTION, NJ, September 18, 2020 -- Biotech Support Group reports ona journal article describingthe efficiency and simplicity of hemoglobin depletion products forWestern blot analysis of reticulocytes (Retics) lysates.

Thecitation is:

Hojo-SouzaNS, de Azevedo PO, de Castro JT, Teixeira-Carvalho A, Lieberman J, etal. (2020) Contributions of IFN-γ and granulysin to the clearance ofPlasmodium yoelii blood stage. PLOS Pathogens 16(9): e1008840.https://doi.org/10.1371/journal.ppat.1008840

Theauthors describe how P.vivax-infectedRetics (iRetics) express human leukocyte antigen class I (HLA-I),which are recognized by CD8+ T cells and killed by granulysin (GNLY)and granzymes. However, how Plasmodium infection induces MHC-Iexpression on Retics is unknown. In addition, whether GNLY helpscontrol Plasmodium infection invivohas not been studied. To remove interferences associated withHemoglobin, the article states, “For western blot analysis,erythroblasts pellets were resuspended in RIPA Buffer (Sigma)…. TheRetics were treated with HemogloBind (Biotech Support Group) …”.The research results indicate that in addition to previouslydescribed mechanisms, IFN-γ promotes host resistance to theRetic-tropic P.yoelii17XNL strain by promoting MHC-I expression on iRetics that becometargets for CD8+ cytotoxic T lymphocytes and GNLY.

“Iam pleased to see another use for HemogloBind^TMin malaria research of reticulocytes. With the efficiency ofHemoglobin removal that our products provide, investigators can nowstudy the many aspects of red cells as they relate to disease.Finally, we can provide a simple method to remove Hemoglobininterference, as this can often be a problem with immunoassay andWestern blot analysis. Furthermore, this article demonstratescompatibilitywith the commonly used RIPA lysis buffer.”, statesSwapan Roy, Ph.D., President and Founder of Biotech Support Group.

Formore information on all of our Hemoglobin removal products, visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, and HemogloBind™ and HemoVoid™ for hemoglobinremoval. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, gotohttp://www.biotechsupportgroup.com

ForBusiness Development, Contact:
MatthewKuruc 732-274-2866, [email protected]